AI Biotech Firm Generate Biomedicines (GENB.US) Files for U.S. IPO to Raise $100 Million, Lead Asthma Therapy in Phase III

Generate Biomedicines (GENB.US), an AI biotech company focused on asthma treatment, filed with the U.S. Securities and Exchange Commission on Wednesday to raise up to $100 million through an initial public offering. The company leverages an AI drug discovery platform to develop therapies for severe asthma, with its lead candidate already entering the pivotal Phase III clinical trial stage.

Generate Biomedicines claims that its AI-driven Generate platform is a tightly integrated "design-build-test-learn" closed-loop system, aimed at generating proprietary data with therapeutic relevance and differentiated molecular solutions. The company stated that the potential of its technology has been validated by the successful advancement of three computationally designed proteins into human clinical trials, with the most advanced being GB-0895, an investigational long-acting anti-thymic stromal lymphopoietin monoclonal antibody, which is currently in the patient recruitment phase for a pivotal Phase III clinical trial for severe asthma.

This Somerville, Massachusetts-based company was founded in 2018 and plans to list on the Nasdaq under the ticker symbol "GENB." The company secretly filed for its IPO on December 23, 2025. The offering is jointly led by Goldman Sachs, Morgan Stanley, Piper Sandler, Guggenheim Securities, and Cantor Fitzgerald as book-running managers.